Related Experiment Videos

Thromboprophylaxis for acetabular injuries in the UK What prophylaxis is used?

J M Geoghegan1, K Hassan, D Calthorpe

  • 1Department of Trauma and Orthopaedics, Derbyshire Royal Infirmary, Derby DE1 2QY, United Kingdom. john.geoghegan@ntlworld.com <john.geoghegan@ntlworld.com>

Injury
|July 29, 2006
PubMed

Insights

UK acetabular trauma care lacks national coordination, leading to delayed surgeries and inconsistent thromboprophylaxis. Current practices show varied approaches to preventing blood clots, highlighting a need for standardized guidelines in managing pelvic and acetabular injuries.

Area of Science:

  • Orthopedic Surgery
  • Traumatology
  • Vascular Surgery

Background:

  • Chronic underfunding and lack of a coordinated national strategy impact acetabular trauma patient care in the UK.
  • Prolonged recumbancy is a significant issue for patients with acetabular injuries due to management gaps.

Purpose of the Study:

  • To investigate current clinical practices in UK specialist pelvic and acetabular units.
  • To assess the time to surgery, thromboprophylaxis, and surveillance methods for acetabular trauma patients.

Main Methods:

  • A postal questionnaire was distributed to specialist pelvic and acetabular units across the UK.
  • Data collected from 21 units and 37 surgeons regarding management protocols.

Main Results:

  • The mean time to surgery for acetabular trauma in the UK is 8.5 days.
  • Chemical thromboprophylaxis (LDH or LMWH) is universal, while mechanical prophylaxis is used in 67% of units.
  • Clinical surveillance for thromboembolism is common (90%), but routine radiological surveillance (ultrasound Doppler) is rare (10%).

Conclusions:

  • There is a lack of consensus on thromboprophylaxis and surveillance for acetabular trauma in the UK.
  • The absence of a dedicated surgeon directory and standardized protocols hinders optimal patient care.
  • A coordinated national approach is needed to improve outcomes for acetabular trauma patients.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...